Core Viewpoint - China Antibody-B (03681) has entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute of Science (SYSU-IAS) to enhance joint research and development in the biomedical field over a three-year period [1] Group 1: Strategic Cooperation - The cooperation agreement aims to leverage the strengths of both parties to accelerate the development of innovative drugs and facilitate the translation of research results into clinical applications globally [1] - The collaboration will adopt a project-driven model focusing on resource sharing and efficient communication [1] Group 2: Resource Utilization - The partnership allows the company to directly utilize SYSU-IAS's comprehensive laboratory facilities, experimental animal supply resources (especially non-primate animals), and valuable data assets [1] - These elements are considered key factors in promoting innovative drug research and ensuring the sustainable development of the company's R&D efforts [1]
港股异动 | 中国抗体-B(03681)早盘涨超5% 与中山大学香港高等研究院订立全面战略合作协议